Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Figure 2 Univariate and Multivariate Cox analyses of prognostic factors of 5-year survival in this group.
N stage (N0 and N1 vs N2 and N3), T stage (T1 and T2 vs T3 and T4), TNM stage (stage II and stage III), surgery type (Total gastrectomy vs Partial gastrectomy), Neoadjuvant therapy (No vs Yes) and Borrmann classification (Superficial Type, Type I and Type II vs Type III and Type IV) are the prognosis factor of gastric cancer patients.
- Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589